Press release
Fabry Disease Treatment Market to Reach USD 4.09 Billion by 2031, Driven by Enzyme Replacement and Gene Therapy Advances
Fabry Disease Treatment Market Size & Trends | Mordor Intelligence
Introduction:
The fabry disease treatment market is expected to grow from USD 2.63 billion in 2025 to USD 2.83 billion in 2026 and is forecast to reach USD 4.09 billion by 2031 at 7.63% CAGR over 2026-2031. North America currently holds the largest share of the market, while Asia-Pacific is emerging as the fastest-growing region. The market expansion is fueled by advancements in gene and mRNA therapies, broader newborn screening, and supportive orphan-drug policies, which are collectively enhancing access to treatment for patients with Fabry disease.
Report Overview:
https://www.mordorintelligence.com/industry-reports/fabry-disease-treatment-market?utm_source=openpr
Key Trends in the Fabry Disease Treatment Market:
The fabry disease treatment market is being shaped by several significant trends:
Growing Clinical Recognition: Increased awareness and identification of late-onset Fabry disease variants have expanded the addressable patient population. Improved screening in renal and cardiology clinics, along with newborn testing programs, is bringing more patients under treatment earlier, enhancing outcomes.
Shift Toward Advanced Therapies: Traditional bi-weekly enzyme replacement therapies remain dominant, but there is a growing shift toward once-only gene therapies and oral substrate reduction therapies. These newer modalities reduce the treatment burden, improve adherence, and offer the potential for long-term clinical benefits.
Supportive Orphan-Drug Regulations: Orphan-drug incentives, including seven-year exclusivity, tax credits, and priority review vouchers, are encouraging pharmaceutical companies to invest in rare-disease therapies. These policies help ensure continued innovation and sustained market growth.
Expansion of Home-Infusion and Telemedicine Services: The growth of home-based treatment services and telehealth solutions is reducing administration challenges and supporting patient compliance, especially for intravenous therapies, which dominate the current treatment landscape.
Check out more details and stay updated with the latest industry trends, including the Japanese version for localized insights:
https://www.mordorintelligence.com/ja/industry-reports/fabry-disease-treatment-market?utm_source=openpr
Market Segmentation:
The fabry disease treatment market is segmented by treatment type, route of administration, distribution channel, and geography.
By Treatment:
Enzyme Replacement Therapy (ERT) - holds the majority share of the market
Gene Therapy - projected to grow at a high CAGR
Substrate Reduction Therapy
Oral chaperon therapy
others
By Route of Administration:
Intravenous - currently the dominant delivery method
Subcutaneous - expected to grow steadily
Oral - emerging as a convenient alternative
By Distribution Channel:
Hospital Pharmacies - currently lead market share
Specialty Pharmacies - showing the highest projected growth
Retail Pharmacies
Online Pharmacies
By Geography:
North America - largest market share
Europe - steady growth due to supportive reimbursement policies
Asia-Pacific - fastest-growing market
Middle East & Africa
South America
Key Players in the Fabry Disease Treatment Market:
The fabry disease treatment market features several major players driving innovation and expansion. Companies offering enzyme replacement therapies remain dominant, while newer entrants focusing on gene therapies are gaining prominence. Strategic collaborations, licensing agreements, and investment in R&D are key factors shaping competitive dynamics. Leading pharmaceutical companies are actively pursuing orphan-drug designations, accelerated approval pathways, and clinical trials to expand their portfolios. The competitive environment also benefits from manufacturing advancements and the development of biosimilars, which lower entry barriers and enhance treatment accessibility.
Sanofi (Genzyme Corporation)
Takeda Pharmaceutical Company Limited
Amicus Therapeutics, Inc
ISU ABXIS
JCR Pharmaceuticals Co., Ltd.
Conclusion:
The fabry disease treatment market is poised for sustained growth through 2031, supported by increasing awareness of the disease, rising adoption of advanced therapies, and favorable regulatory policies. Enzyme replacement therapy continues to dominate, but gene therapy and oral therapies are expected to capture a growing share of the market. North America remains the largest market, while Asia-Pacific offers significant growth opportunities. Expansion of home-infusion services, telemedicine, and broader screening programs are enhancing patient access and adherence. As investment in rare-disease treatments rises globally, the fabry disease treatment market is expected to maintain steady growth, presenting opportunities for manufacturers, healthcare providers, and investors.
For complete market analysis, please visit the Mordor Intelligence page:
https://www.mordorintelligence.com/industry-reports/fabry-disease-treatment-market?utm_source=openpr
Industry related Reports:
Gaucher Disease Drugs Market : The Gaucher Disease Drugs Market report segments the industry into By Disease Type (Type 1, Type 2, Type 3), By Therapy Type (Enzyme Replacement Therapy, Substrate Replacement Therapy, Other Therapies), By Route of Administration (Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).
Get more Insights : https://www.mordorintelligence.com/industry-reports/gaucher-disease-drugs-market?utm_source=openpr
Filgrastim Market : The Filgrastim Market is Segmented by Drug Type (Biologics and Biosimilars), Distribution Channel (Offline Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America).
Get more Insights : https://www.mordorintelligence.com/industry-reports/filgrastim-market?utm_source=openpr
Fibrotic Disease Treatment Market : The Fibrotic Disease Treatment Market report segments the industry into By Treatment (Medication, Organ Transplantation, Oxygen Therapy, Others), By Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, Others), By End User (Hospitals, Academic And Research Institutes, Others), and Geography (North America, Europe, Asia-Pacific, Middle East And Africa, South America).
Get more Insights : https://www.mordorintelligence.com/industry-reports/fibrotic-disease-treatment-market?utm_source=openpr
About Mordor Intelligence:
Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.
With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.
Mordor Intelligence, 11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli, Hyderabad, Telangana - 500032, India
For any inquiries or to access the full report, please contact:
media@mordorintelligence.com
https://www.mordorintelligence.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fabry Disease Treatment Market to Reach USD 4.09 Billion by 2031, Driven by Enzyme Replacement and Gene Therapy Advances here
News-ID: 4360428 • Views: …
More Releases from Mordor Intelligence
Egypt Residential Construction Market to Reach USD 29.96 Billion by 2031 as Gove …
Mordor Intelligence has published a new report on the offering a Egypt Residential Construction comprehensive analysis of trends, growth drivers, and future projections
Egypt Residential Construction Market Overview
According to Mordor Intelligence, the Egypt residential construction market size was valued at USD 18.80 billion in 2025 and expanded to USD 20.32 billion in 2026, with the market forecast to reach USD 29.96 billion by 2031. This growth outlook reflects the…
Canned Meat Market Size to Reach USD 22.69 Billion by 2031 as Protein Demand and …
The global canned meat market size is projected to expand from usd 18.61 billion in 2026 to usd 22.69 billion by 2031, registering a cagr of 4.04% during the forecast period, according to Mordor Intelligence. This steady expansion reflects rising reliance on shelf-stable protein sources, changing household structures, and growing institutional procurement across both developed and emerging economies. The canned meat industry continues to benefit from its dual positioning as…
Canned Alcoholic Beverages Market Size to Reach USD 48.78 Billion by 2030 as RTD …
The Global canned alcoholic beverages market size is projected to expand from USD 34.81 billion in 2025 to USD 48.78 billion by 2030, registering a CAGR of 6.98% during the forecast period, according to Mordor Intelligence. This steady expansion reflects a structural shift in alcohol consumption toward convenient, portable, and premium-ready formats.
The Canned Alcoholic Beverages Industry is benefiting from changing lifestyle patterns, growing demand for ready-to-drink (RTD) options, and increasing…
Automotive Green Tires Market Size Expected to Reach USD 247.9 Billion by 2031 - …
Introduction
The Automotive Green Tires Market is gaining traction as sustainability, fuel efficiency, and emissions reduction become central priorities for automotive manufacturers and regulators. According to Mordor Intelligence, the Automotive Green Tires market size is expected to grow from USD 133.73 billion in 2025 to USD 148.22 billion in 2026, and is forecast to reach USD 247.90 billion by 2031, registering a CAGR of 10.84% during the 2026-2031 forecast period.…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
